Dr. Reddys Laboratories Ltd.

Dr. Reddys Laboratories is currently trading at Rs. 2569.00, up by 39.70 points or 1.57% from its previous closing of Rs. 2529.30 on the BSE.

The scrip opened at Rs. 2540.05 and has touched a high and low of Rs. 2593.65 and Rs. 2540.05 respectively. So far 28658 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2660.10 on 10-Sep-2018 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and low of the scrip stood at Rs. 2660.10 and Rs. 2490.55 respectively. The current market cap of the company is Rs. 42902.95 crore.

The promoters holding in the company stood at 26.79%, while Institutions and Non-Institutions held 44.27% and 14.60% respectively.

Dr. Reddy's Laboratories has launched Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (Neostigmine Methylsulfate) Injection in the US market, approved by the US Food and Drug Administration (USFDA).

The Bloxiverz brand and generic had US sales of approximately $111 million MAT for the most recent twelve months ending in July 2018 according to IMS Health. Dr. Reddy's Neostigmine Methylsulfate Injection, USP is available in 5 mg/10 ml and 10 mg/10 ml multi-dose vials.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.